- Home
- PHGE vs BREA Comparison
PHGE vs BREA Comparison
Compare PHGE & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- BREA
- Stock Information
- Founded
- PHGE 2015
- BREA 2022
- Country
- PHGE Israel
- BREA Ireland
- Employees
- PHGE N/A
- BREA N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- PHGE Health Care
- BREA Consumer Discretionary
- Exchange
- PHGE Nasdaq
- BREA Nasdaq
- Market Cap
- PHGE 12.6M
- BREA 14.8M
- IPO Year
- PHGE N/A
- BREA 2023
- Fundamental
- Price
- PHGE $0.48
- BREA $7.58
- Analyst Decision
- PHGE Strong Buy
- BREA
- Analyst Count
- PHGE 1
- BREA 0
- Target Price
- PHGE $15.00
- BREA N/A
- AVG Volume (30 Days)
- PHGE 389.8K
- BREA 216.2K
- Earning Date
- PHGE 11-13-2025
- BREA 01-01-0001
- Dividend Yield
- PHGE N/A
- BREA N/A
- EPS Growth
- PHGE N/A
- BREA N/A
- EPS
- PHGE N/A
- BREA N/A
- Revenue
- PHGE N/A
- BREA $2,988,009.00
- Revenue This Year
- PHGE N/A
- BREA N/A
- Revenue Next Year
- PHGE N/A
- BREA N/A
- P/E Ratio
- PHGE N/A
- BREA N/A
- Revenue Growth
- PHGE N/A
- BREA 151.51
- 52 Week Low
- PHGE $0.34
- BREA $5.00
- 52 Week High
- PHGE $1.16
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- PHGE 50.36
- BREA 63.08
- Support Level
- PHGE N/A
- BREA $5.87
- Resistance Level
- PHGE $0.51
- BREA $6.42
- Average True Range (ATR)
- PHGE 0.03
- BREA 0.92
- MACD
- PHGE -0.03
- BREA 0.16
- Stochastic Oscillator
- PHGE 85.12
- BREA 20.50
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.